3. Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
Price: $5.01 per share
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) gained the 3rd place in our list of the top 10 small-cap FDA catalyst biotech stocks. The company is positioning itself as one of the most differentiated late-stage gene therapy stocks in 2026, combining multiple high-impact rare disease programs with disciplined financial management and clear regulatory catalysts. Following its fourth quarter and full-year 2025 financial results, Rocket Pharma reinforced its leadership in cardiovascular gene therapy, highlighted by plans to resume the pivotal Phase 2 trial of RP-A501 for Danon disease in the first half of 2026 after the FDA lifted the clinical hold in under three months. With additional patients set to be dosed under a recalibrated regimen and continued alignment with the FDA, the Danon disease program remains a central value driver in the RCKT stock narrative.
Equally significant is KRESLADI™ for severe leukocyte adhesion deficiency-I (LAD-I), which is on track for a March 28, 2026 PDUFA date after the FDA accepted the resubmitted biologics license application. Approval would not only validate Rocket’s lentiviral gene therapy platform but could also make the company eligible for a Rare Pediatric Disease Priority Review Voucher, a potential non-dilutive asset that may strengthen the balance sheet. In parallel, Rocket is advancing RP-A601 for PKP2 arrhythmogenic cardiomyopathy while preparing to dose the first patient in its Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy in mid-2026, further expanding its AAV-based cardiovascular pipeline and reinforcing its multi-platform gene therapy strategy.
Financially, Rocket Pharmaceuticals ended 2025 with approximately $188.9 million in cash, cash equivalents, and investments, providing operational runway into the second quarter of 2027. Research and development expenses declined year-over-year to $142.0 million, reflecting disciplined resource allocation and organizational realignment, while net loss narrowed to $223.1 million from $258.7 million in the prior year. This combination of cost control, focused clinical execution, and advancing late-stage assets strengthens the investment case for Rocket Pharma as it moves through multiple regulatory and clinical milestones.
As a fully integrated biotechnology company targeting rare genetic disorders with high unmet medical need, Rocket Pharmaceuticals offers exposure to transformative gene therapy innovation across both cardiovascular and hematology indications. With a pivotal trial resuming in Danon disease, a near-term FDA decision for KRESLADI™, and new first-in-human data anticipated in BAG3-associated dilated cardiomyopathy, RCKT stock presents a catalyst-rich biotech growth story supported by a diversified pipeline and a clear strategic roadmap in the expanding gene therapy market.
Click next to see the following stock...
